with a higher total disease activity score (SLEDAI ≥6) (OR 9.9, 95% CI 2.1 to 49.9, p=0.0056), neither of the single SLEDAI items and organ manifestations including musculoskeletal manifestations was associated with physical inactivity. Interestingly, the study could not detect any statistical difference in organ manifestations and SLEDAI scores between patients with moderate and high PA. According to the patient's report, the main SLE-related reasons "not to be physically active" for all three groups were "lupus flare" (35.6%), "fatigue" (26.9%) as well as "joint complaints" (15.7%). The main general barriers for PA were "comorbidity" (35,6%) and "lack of motivation" (26,9%). Furthermore, the subjective impact of "bad weather conditions" on physical activity was significantly greater in physically inactive patients compared with the two other groups (the patient's report: 6.58±2.3 vs. 3.49±0.7, p<0.03).
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Conclusions:
The main reason for the patients not to be physically active was fatigue and pain. The study also indicates that not only somatic symptoms could decrease the levels of PA in SLE patients. Further research on psychological factors is needed. The study underlines the need for management strategies that specifically target physical activity as a part of an overall SLE management program. They differ substantially from previously used AECG criteria in that they consider systemic involvement (defined as ESSDAI score ≥1) as well as sicca symptoms as entry criteria before applying a weighted score. Evaluation of the concordance and differences between the two sets of criteria in independent patient populations is mandatory to establish how future clinical studies using the new criteria will be comparable to previously published studies. Major salivary gland ultrasonography (SGUS) has demonstrated promising diagnostic performance in previous studies, but was not included in these new classification criteria. Methods: This cross-sectional study was conducted in the monocentric Brittany cohort (DIApSS cohort) of patients with suspected pSS (sicca symptoms, parotidomegaly or extraglandular manifestations suggestive of pSS). All patients had standardized clinical examination, basic biology, immunological tests and minor labial salivary gland biopsy. SGUS in mode B was performed by the same experienced operator, who was blinded to the diagnosis. Agreement between the two sets of criteria was assessed using Cohen's κ coefficient and the characteristics of discordant patients were detailed. 
Background:
Patients with systemic lupus erythematosus have a very high burden of comorbidities. Identification and management of these comorbidities are critical for optimal medical care to this population. Objectives: To assess the prevalence of comorbidities in SLE patients with pulmonary involvement. Methods: In a cross-sectional study, patients who fulfiled the SLICC (2012) classification criteria for SLE, were recruited from Rheumatology Departement. Data collection included demographics, disease duration, physician-rated indices of disease activity (by SLAM), damage (by SLICC/ACR DI) and Charlson comorbidity Index. The pulmonary involvement was assessed by chest X-ray, EcoCG Doppler and pulmonary functional tests. Results: The study included 106 patients (97 women, 9 males) with a mean age (±SD) of 41,1±12,6 yrs, mean disease duration of 90,3±87,3 months. The disease activity by SLAM was 11±5,17 points and mean SLICC/ACR DI 1,9±2,4 points (66% of patients had at least 1 point). Pulmonary assessment revealed that 45 (42,5%) patients had different types of pulmonary involvement due to lupus: pleuritis -24 patients, pneumonitis -1 patient, pulmonary embolism -4 patients, interstitial lung disease -15, shrinking lung syndrome -1 and pulmonary arterial hypertension -9 patients. The most frequent comorbidities in study group were: arterial hypertension -in 57 (53,7%) cases, from which 33 (57,9%) patients had pulmonary involvement and 24 (42,1%) without, obesity (BMI>30 kg/m 2 ) had 29 (27,4%) patients, from which 17 (58,6%) with lung involvement and 12 (41,4%) without, anemia (Hb<110g/l) had 24 (22,6%) patients, from them 14 (58,3%) with lung disease and 10 (41,7%) patients -without, heart failure (I-II NYHA) had 23 (21,7%) patients, from them 20 (86,9%) were with lung implication, thyroiditis had 22 (20,8%) and 15 (68,2%) of them were with pulmonary involvement, diabetes mellitus type II had only 6 (5,7%) patients and half of them had lung disease. Assessing the impact of associated diseases through Charlson comorbidity index, we found that the score for patients diagnosed with damage to the respiratory system was twice as big vs. patients without respiratory impairment from SLE (6,3±2,4 vs. 3,4±1,4 points). Also, Charlson comorbidity score ≥1 was identified as a risk factor for lung involvement (OR 5, 5294, 95% CI 2, 91, p<0, 01) . Evaluation of disease activity by SLAM showed that patients with lung involvement have a higher disease activity vs. patients without (13,9±6,0 vs. 8,9±4,0, p<0,05) . Conclusions: On the one hand, according to our results patients with SLE and pulmonary involvement have a higher prevalence of comorbidities comparative with patients without them. Hypertension was found to be the most common comorbidity and it was determined in 73,3% of patients with impaired respiratory system (p<0,01). On the other hand, association of comorbidities (Charlson comorbidity score ≥1) was identified as a risk factor for lung lesions. 
